A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

May 19, 2020

Study Completion Date

November 17, 2020

Conditions
Hidradenitis SuppurativaAcne InversaSuppurative Hidradenitis
Interventions
DRUG

bermekimab

bermekimab 2 mL (200 mg/mL) pre-filled syringe

DRUG

placebo

placebo 2 mL pre-filled syringe

Trial Locations (33)

10029

Icahn School of Medicine at Mount Sinai, New York

23233

Dominion Medical Associates, Inc., Richmond

30328

Advanced Medical Research, Sandy Springs

31406

Meridian Clinical Research, LLC, Savannah

31904

Columbus Regional Research Institute, Columbus

32819

Accel Clinical Research, Orlando

32958

Physica Clinical Research, Sebastian

33134

Florida Academic Dermatology Centers, Coral Gables

33145

Floridian Research Institute, Miami

33155

Florida International Medical Research, Miami

33166

Doral Medical Research, Doral

33175

P&S Research, LLC, Miami

33180

Visionary Investigators Network, Aventura

33406

Integrated Clincal Research LLC, West Palm Beach

33613

Avita Clinical Research, Tampa

Forcare Clinical Research, Inc., Tampa

38358

Clinical Research Solutions, LLC, Milan

43213

ClinOhio Research Services, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

46256

Dawes Fretzin Clinical Research Group, Indianapolis

47906

Randall Dermatology & Cosmetic Surgery, West Lafayette

48084

Revival Research Institute, LLC, Troy

48326

Oakland Hills Dermatology, Auburn Hills

63130

Washington University in St. Louis, St Louis

70605

Clinical Trials of SWLA, Lake Charles

70808

Meridian Clinical Research, LLC, Baton Rouge

78213

Progressive Clinical Research, San Antonio

85295

Desert Sky, Gilbert

90033

University of Southern California, Los Angeles

90045

Dermatology Research Associates, Los Angeles

92647

Marvel Clinical Research, Huntington Beach

92705

Syrentis Clinical Research, Santa Ana

Wolverine Clinical Trials, Santa Ana

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter